Search Results - "PASTAN, Ira"

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation by Mazor, Ronit, Pastan, Ira

“…Immunotoxins are cytolytic fusion proteins developed for cancer therapy, composed of an antibody fragment that binds to a cancer cell and a protein toxin…”
Get full text

Advances in Anticancer Immunotoxin Therapy by Alewine, Christine, Hassan, Raffit, Pastan, Ira

“…Immunotoxins are a novel class of antibody‐conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an…”
Get full text

The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene by Gottesman, Michael M, Pastan, Ira H

Get full text

A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer by Weldon, John E., Pastan, Ira

“…Pseudomonas exotoxin A (PE) is a highly toxic protein secreted by the opportunistic pathogen Pseudomonas aeruginosa. The modular structure and corresponding…”
Get full text

Mesothelin Immunotherapy for Cancer: Ready for Prime Time? by Hassan, Raffit, Thomas, Anish, Alewine, Christine, Le, Dung T, Jaffee, Elizabeth M, Pastan, Ira

“…Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung…”
Get full text

Strategies to Reduce the Immunogenicity of Recombinant Immunotoxins by Mazor, Ronit, King, Emily M., Pastan, Ira

“…Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv that targets a cancer antigen…”
Get full text

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient's Bedside to Evaluation in Preclinical Models by Leshem, Yasmin, Pastan, Ira

“…Immunotoxins are protein drugs composed of a targeting domain genetically fused to a protein toxin. One killing domain being explored is a truncated exotoxin A…”
Get full text

Distinct Roles of Segregated Transmission of the Septo-Habenular Pathway in Anxiety and Fear by Yamaguchi, Takashi, Danjo, Teruko, Pastan, Ira, Hikida, Takatoshi, Nakanishi, Shigetada

“…The posterior septum consisting of the triangular septum (TS) and the bed nucleus of the anterior commissure (BAC) is predominantly linked with the medial…”
Get full text

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia by Haso, Waleed, Lee, Daniel W., Shah, Nirali N., Stetler-Stevenson, Maryalice, Yuan, Constance M., Pastan, Ira H., Dimitrov, Dimiter S., Morgan, Richard A., FitzGerald, David J., Barrett, David M., Wayne, Alan S., Mackall, Crystal L., Orentas, Rimas J.

“…Immune targeting of B-cell malignancies using chimeric antigen receptors (CARs) is a promising new approach, but critical factors impacting CAR efficacy remain…”
Get full text

Mechanisms of Resistance to Immunotoxins Containing Pseudomonas Exotoxin A in Cancer Therapy by Dieffenbach, Michael, Pastan, Ira

“…Immunotoxins are a class of targeted cancer therapeutics in which a toxin such as exotoxin A (PE) is linked to an antibody or cytokine to direct the toxin to a…”
Get full text

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors by Yu, Xin, Dobrikov, Mikhail, Keir, Stephen T, Gromeier, Matthias, Pastan, Ira H, Reisfeld, Ralph, Bigner, Darell D, Chandramohan, Vidyalakshmi

“…Standard treatment, unfortunately, yields a poor prognosis for patients with primary or metastatic cancers in the central nervous system, indicating a…”
Get full text

Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response by Zhang, Jingli, Khanna, Swati, Jiang, Qun, Alewine, Christine, Miettinen, Markku, Pastan, Ira, Hassan, Raffit

“…The purpose of this study was to evaluate the antitumor efficacy of the reduced immunogenicity anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against…”
Get full text

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia by KREITMAN, Robert J, TALLMAN, Martin S, ROBAK, Tadeusz, COUTRE, Steven, WILSON, Wyndham H, STETLER-STEVENSON, Maryalice, FITZGERALD, David J, LECHLEIDER, Robert, PASTAN, Ira

“…To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in…”
Get full text

Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics by Nagata, Satoshi, Pastan, Ira

“…Immunogenicity of non-human proteins with useful therapeutic properties has prevented their development for use in the therapy of disease. However, this class…”
Get full text

Possible role of complement factor H in podocytes in clearing glomerular subendothelial immune complex deposits by Zoshima, Takeshi, Hara, Satoshi, Yamagishi, Masakazu, Pastan, Ira, Matsusaka, Taiji, Kawano, Mitsuhiro, Nagata, Michio

“…Podocytes are known to express various complement factors including complement factor H (CFH) and to promote the removal of both subendothelial and…”
Get full text

C-type lectin-like receptor (CLEC)-2, the ligand of podoplanin, induces morphological changes in podocytes by Tanaka, Keiko, Tanaka, Masafumi, Watanabe, Nobuo, Ito, Masatoshi, Pastan, Ira, Koizumi, Masahiro, Matsusaka, Taiji

“…Podoplanin (PDPN) is intensely expressed on the podocyte membrane in an evolutionally conserved manner. CLEC-2, the endogenous ligand of PDPN, is highly…”
Get full text

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P by KREITMAN, Robert J, HASSAN, Raffit, FITZGERALD, David J, PASTAN, Ira

“…Purpose: To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin…”
Get full text

3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors by Li, Zhongwei, Araoka, Toshikazu, Wu, Jun, Liao, Hsin-Kai, Li, Mo, Lazo, Marta, Zhou, Bing, Sui, Yinghui, Wu, Min-Zu, Tamura, Isao, Xia, Yun, Beyret, Ergin, Matsusaka, Taiji, Pastan, Ira, Rodriguez Esteban, Concepcion, Guillen, Isabel, Guillen, Pedro, Campistol, Josep M., Izpisua Belmonte, Juan Carlos

“…Transit-amplifying nephron progenitor cells (NPCs) generate all of the nephrons of the mammalian kidney during development. Their limited numbers, poor…”
Get full text

Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers by Alewine, Christine, Xiang, Laiman, Yamori, Takao, Niederfellner, Gerhard, Bosslet, Klaus, Pastan, Ira

“…The RG7787 mesothelin-targeted recombinant immunotoxin (RIT) consists of an antibody fragment targeting mesothelin (MSLN) fused to a 24-kD fragment of…”
Get full text

Removing T-cell epitopes with computational protein design by King, Chris, Garza, Esteban N., Mazor, Ronit, Linehan, Jonathan L., Pastan, Ira, Pepper, Marion, Baker, David

“…Immune responses can make protein therapeutics ineffective or even dangerous. We describe a general computational protein design method for reducing…”
Get full text